Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
HER2 gene amplification
CUI: C1512127
Disease: HER2 gene amplification
0.050 GeneticVariation BEFREE Drug resistance becomes inevitable due to the emergence of the second-site EGFR T790M mutation within exon 20, MET and HER2 amplification, small cell histologic transformation and rare secondary BRAF mutations. 31132355 2019
HER2 gene amplification
CUI: C1512127
Disease: HER2 gene amplification
0.050 GeneticVariation BEFREE In 23 EGFR mutant cases with acquired resistance to targeted therapy, plasma NGS detected potential resistance mechanisms, including EGFR T790M and C797S mutations and ERBB2 amplification. 30891595 2019
HER2 gene amplification
CUI: C1512127
Disease: HER2 gene amplification
0.050 GeneticVariation BEFREE Several mechanisms have been identified, including EGFR T790M mutation and HER2 amplification. 30295016 2018
HER2 gene amplification
CUI: C1512127
Disease: HER2 gene amplification
0.050 GeneticVariation BEFREE Cancerous cells resist EGFR tyrosine kinase inhibitors (TKIs) through various mechanisms, the most commonly reported ones are the T790M mutation and HER2 amplification. 28754471 2017
HER2 gene amplification
CUI: C1512127
Disease: HER2 gene amplification
0.050 GeneticVariation BEFREE Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechanism of resistance to osimertinib, this study was addressed to investigate the potential of combining osimertinib with trastuzumab emtansine (T-DM1) in order to improve the efficacy of osimertinib and delay or overcome resistance in NSCLC cell lines with EGFR activating mutation and with T790M mutation or HER-2 amplification. 29202823 2017